Subscribe to RSS
DOI: 10.1055/s-0040-1709186
Unique Clinical and Histological Features of Placental Mesenchymal Dysplasia Complicated by Severe Preeclampsia in the Midtrimester
Publication History
22 January 2020
20 February 2020
Publication Date:
28 March 2020 (online)
Abstract
Detailed clinical and pathological features of placental mesenchymal dysplasia (PMD) complicated by preeclampsia (PE) are unknown. A 39-year-old nulliparous woman was referred at 19 weeks gestation. Ultrasound examination identified a fetus with severe growth restriction (−2.8 SD) and a markedly thickened placenta with many cystic structures suggestive of PMD. At 21 weeks, the patient developed severe hypertension (180/95 mm Hg) with marked proteinuria and an elevated serum soluble fms-like tyrosine-kinase-1 (sFlt-1) level (47,000 pg/L). The pregnancy was terminated to protect maternal health. Placental weight was 450 g and no histopathological findings of either proliferation or dysplasia were observed in the trophoblast. Villous chromosome examination revealed a 46XX karyotype, consistent with the diagnosis of PMD. In addition to the pathological findings of vascular endothelial dysfunction characteristic of the placenta in PE cases, enhanced expression of sFlt-1 in the syncytiotrophoblast of the enlarged villi was confirmed by immunohistochemistry as a novel finding in this condition. Monitoring of the serum sFlt-1 value is suggested to be a useful predictor of the pathological change associated with extremely early severe PE in PMD cases.
-
References
- 1 Moscoso G, Jauniaux E, Hustin J. Placental vascular anomaly with diffuse mesenchymal stem villous hyperplasia. A new clinico-pathological entity?. Pathol Res Pract 1991; 187 (2-3): 324-328
- 2 Toru HS, Aytekin EÇ, Sanhal CY. , et al. We can diagnose it if we consider it. Diagnostic pitfall for placenta: placental mesenchymal dysplasia. Turk Patoloji Derg 2018; 34 (01) 100-103
- 3 Pham T, Steele J, Stayboldt C, Chan L, Benirschke K. Placental mesenchymal dysplasia is associated with high rates of intrauterine growth restriction and fetal demise: a report of 11 new cases and a review of the literature. Am J Clin Pathol 2006; 126 (01) 67-78
- 4 Takayama M, Soma H, Yaguchi S. , et al. Abnormally large placenta associated with Beckwith-Wiedemann syndrome. Gynecol Obstet Invest 1986; 22 (03) 165-168
- 5 Kuwabara Y, Shima Y, Araki T, Shin S. Mesenchymal stem villous hyperplasia of the placenta and fetal growth restriction. Obstet Gynecol 2001; 98 (5 Pt 2): 940-943
- 6 Surti U, Hill LM, Dunn J, Prosen T, Hoffner L. Twin pregnancy with a chimeric androgenetic and biparental placenta in one twin displaying placental mesenchymal dysplasia phenotype. Prenat Diagn 2005; 25 (11) 1048-1056
- 7 Duffett L, Rodger M. LMWH to prevent placenta-mediated pregnancy complications: an update. Br J Haematol 2015; 168 (05) 619-638
- 8 Na ED, Lee KJ, Kim M-J, Yi H-J, Kim J-Y. Placental mesenchymal dysplasia associated with severe preeclampsia: a case report. Korean J Obstet Gynecol 2011; 54: 459-463
- 9 Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93 (01) 260-266
- 10 Levine RJ, Lam C, Qian C. , et al; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355 (10) 992-1005